Gynecologic Oncology Group: Fallopian Tube Neoplasms trials

The registry lists 26 Fallopian Tube Neoplasms studies with Gynecologic Oncology Group as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 7Phase 2 8Phase 3 3No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian CancerTerminatedNCT01275664Not applicableResults posted
• OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete RemissionCompletedNCT00857545Phase 2Results posted
• AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedNCT00574951Phase 2Results posted
• Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube CancerCompletedNCT00569673Phase 2Results posted
• Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00459290Phase 2Results posted
• Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00114166Phase 2Results posted
• Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing ChemotherapyWithdrawnNCT01492920Phase 3
• Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal CancerStatus unknownNCT01372787
• Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerStatus unknownNCT01366183
• Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving ChemotherapyCompletedNCT01080521
• Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182Status unknownNCT01074398
• YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving ChemotherapyTerminatedNCT00899093
• Collecting Tumor Samples From Patients With Gynecological TumorsCompletedNCT00897442
• Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus unknownNCT00719303Phase 3
• Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete RemissionWithdrawnNCT00693342Phase 3
• Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or CarboplatinWithdrawnNCT00369954Phase 2
• Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic MassStatus unknownNCT00238342Not applicable
• Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00066456Phase 1
• Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube CancerCompletedNCT00060359Phase 1
• Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00006235Phase 1
• Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00003967Phase 1
• Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial CancerTerminatedNCT00003624Phase 2
• Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00003385Phase 1
• Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube CancerTerminatedNCT00003382Phase 1
• Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal CancerTerminatedNCT00003380Phase 1
• Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal CancersCompletedNCT00002538Phase 2